619

DEVELOPMENT OF AN ARTIFICIAL INTELLIGENCE BASED MODEL TO PREDICT EARLY RECURRENCE OF NEUROENDOCRINE LIVER METASTASIS FOLLOWING RESECTION

Date
May 19, 2024

Background: Recurrence of neuroendocrine tumor liver metastasis (NELM) following curative-intent resection occurs in a large subset of patients. Artificial intelligence (AI) may help predict outcomes among patients with cancer. We sought to develop an AI based model to predict early recurrence following curative-intent resection of NELM.
Methods: Patients who underwent curative-intent resection for NELM were identified from an international multi-institutional database. Early recurrence was defined as recurrence within 12 months of surgical resection. Different machine learning (ML) and deep learning (DL) techniques were employed to develop prediction models for early recurrence.
Results: 473 NELM patients were randomized into training (n= 378, 79.9%) and testing (n= 95, 20.1%) cohorts. Among 284 (60.0%) patients who developed NELM recurrence with a median follow-up period of 55 months (IQR, 23-94), 118 (41.5%) patients developed an early recurrence. Ten clinicopathological factors were identified as most strongly correlated with early recurrence on correlation heatmap and were used to train the AI models. Among the different AI techniques, an ensemble model consisting of Multi-Layer Perceptron (MLP) and Gradient Boosting (GB) classifiers demonstrated the highest accuracy with area under receiver operating characteristic curve (AUC) of 0.763 (95% CI, 0.705-0.821) and 0.716 (95% CI, 0.593-0.828) in the training and testing cohorts, respectively. Specifically, maximum diameter of the primary neuroendocrine tumor (NET), NELM radiologic tumor burden score (TBS), and bilateral liver involvement were the factors most strongly associated with risk of early NELM recurrence, as demonstrated on the SHAP summary plot (Figure 1). Patients predicted to develop early recurrence had worse 5- (21.4% vs. 37.1%), and 10-year (12.8% vs. 37.1%) recurrence free survival (RFS) versus patients not predicted to recur (p=0.002). Similarly, patients predicted to experience early recurrence had worse 5- (61.6% vs. 90.3%) and 10-year (44.4% vs. 75.8%) overall survival (OS) compared with patients not predicted to recur within 12 months (p=0.03) (Figure 2).
Conclusion: An AI based model demonstrated very good discrimination to predict early recurrence following resection of NELM. AI models such as the one proposed here may help identify which patients benefit the most from curative-intent resection, as well as inform treatment decisions around surgical versus non-surgical treatment options for patients with NELM.
SHAP Summary Plot Showing Factor Weightages

SHAP Summary Plot Showing Factor Weightages

Kaplan Meier Curves for OS

Kaplan Meier Curves for OS


Tracks

Related Products

Thumbnail for EFFECT OF TELEMEDICINE USE ON MEDICAL SPENDING AND HEALTH CARE UTILIZATION AMONG GASTROINTESTINAL CANCER PATIENTS
EFFECT OF TELEMEDICINE USE ON MEDICAL SPENDING AND HEALTH CARE UTILIZATION AMONG GASTROINTESTINAL CANCER PATIENTS
INTRODUCTION: Telemedicine use increased with the COVID-19 pandemic, yet the effect of telemedicine on resource utilization has not been investigated. We sought to characterize the impact of telemedicine on healthcare utilization and medical spending among patients with gastrointestinal (GI) cancer…
Thumbnail for ASSOCIATION OF PREOPERATIVE CHOLANGITIS WITH OUTCOMES AND EXPENDITURES AMONG PATIENTS UNDERGOING PANCREATICODUODENECTOMY
ASSOCIATION OF PREOPERATIVE CHOLANGITIS WITH OUTCOMES AND EXPENDITURES AMONG PATIENTS UNDERGOING PANCREATICODUODENECTOMY
INTRODUCTION: Preoperative cholangitis (PC) is an important risk factor for postoperative morbidity among patients undergoing pancreatic surgery. We sought to characterize the impact of PC on surgical outcomes and healthcare costs…
Thumbnail for TRENDS IN COST SHARING AND CANCER TREATMENT MODALITY UTILIZATION AMONG COMMERCIALLY INSURED PATIENTS WITH GASTROINTESTINAL CANCER
TRENDS IN COST SHARING AND CANCER TREATMENT MODALITY UTILIZATION AMONG COMMERCIALLY INSURED PATIENTS WITH GASTROINTESTINAL CANCER
INTRODUCTION: The cost of healthcare is widely recognized as a substantial barrier to access essential medical care…
Thumbnail for IMPACT OF HOSPITAL FLAGSHIP SYSTEM AFFILIATION ON SURGICAL OUTCOMES FOLLOWING COMPLEX CANCER SURGERY
IMPACT OF HOSPITAL FLAGSHIP SYSTEM AFFILIATION ON SURGICAL OUTCOMES FOLLOWING COMPLEX CANCER SURGERY
INTRODUCTION: Affiliation with a major regional hospital system is often promoted to patients as an opportunity to benefit locally from the same standard of care experienced at the flagship hospital…